Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.

Adult Chromosome Aberrations Hematopoietic Stem Cell Transplantation / adverse effects Humans Leukemia, Myeloid, Acute Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis Retrospective Studies Transplantation Conditioning Transplantation, Homologous

Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
05 2020
Historique:
received: 12 03 2019
accepted: 20 09 2019
pubmed: 29 9 2019
medline: 28 4 2021
entrez: 28 9 2019
Statut: ppublish

Résumé

Cytogenetic risk stratification at diagnosis has long been one of the most useful tools to assess prognosis in acute lymphoblastic leukemia (ALL). To examine the prognostic impact of cytogenetic abnormalities on outcomes after allogeneic hematopoietic cell transplantation, we studied 1731 adults with Philadelphia-negative ALL in complete remission who underwent myeloablative or reduced intensity/non-myeloablative conditioning transplant from unrelated or matched sibling donors reported to the Center for International Blood and Marrow Transplant Research. A total of 632 patients had abnormal conventional metaphase cytogenetics. The leukemia-free survival and overall survival rates at 5 years after transplantation in patients with abnormal cytogenetics were 40% and 42%, respectively, which were similar to those in patients with a normal karyotype. Of the previously established cytogenetic risk classifications, modified Medical Research Council-Eastern Cooperative Oncology Group score was the only independent prognosticator of leukemia-free survival (

Identifiants

DOI: 10.3324/haematol.2019.220756 PMID: 31558669 PMC: PMC7193485
pubmed: 31558669
pii: haematol.2019.220756
doi: 10.3324/haematol.2019.220756
pmc: PMC7193485
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1329-1338

Subventions

Organisme : NCI NIH HHS
ID : R01 CA188523
Pays : United States
Organisme : NHLBI NIH HHS
ID : R21 HL140314
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL128568
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL086773
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI145231
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI145231
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : NHLBI NIH HHS
ID : U24 HL138660
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

Copyright© 2020 Ferrata Storti Foundation.

Références

Blood. 2010 Feb 25;115(8):1490-9
pubmed: 20042721
Cancer Genet. 2012 Sep;205(9):453-8
pubmed: 22939398
Genes Chromosomes Cancer. 2009 Aug;48(8):637-60
pubmed: 19415723
J Clin Oncol. 2014 May 10;32(14):1453-62
pubmed: 24711557
Cancer Genet Cytogenet. 2003 Feb;141(1):1-4
pubmed: 12581891
Haematologica. 2011 Apr;96(4):491-3
pubmed: 21454879
Blood Cancer J. 2013 Jul 05;3:e122
pubmed: 23832069
Biol Blood Marrow Transplant. 2016 Jul;22(7):1212-1217
pubmed: 27044907
PLoS One. 2012;7(7):e40934
pubmed: 22848414
Cancer. 2014 Dec 15;120(24):3958-64
pubmed: 25116331
Leukemia. 1998 May;12(5):805-10
pubmed: 9593285
N Engl J Med. 2009 Jan 29;360(5):470-80
pubmed: 19129520
Blood. 2007 Apr 15;109(8):3189-97
pubmed: 17170120
Pediatr Hematol Oncol. 2015;32(8):535-47
pubmed: 26558423
Indian J Hematol Blood Transfus. 2015 Sep;31(3):322-31
pubmed: 26085716
Comput Methods Programs Biomed. 2011 Jan;101(1):87-93
pubmed: 20724020
Haematologica. 2013 Jun;98(6):945-52
pubmed: 23349309
Cancer. 2017 Feb 1;123(3):459-467
pubmed: 27696391
Leuk Res. 2010 Mar;34(3):e82-4
pubmed: 19573915
Blood. 2010 Jan 14;115(2):206-14
pubmed: 19897583
Blood. 2008 Mar 1;111(5):2563-72
pubmed: 18156492
Leukemia. 2013 Feb;27(2):503-7
pubmed: 22868967
Haematologica. 2017 Jan;102(1):130-138
pubmed: 27561722
J Clin Oncol. 2008 Oct 10;26(29):4791-7
pubmed: 18695255
Blood. 2009 Apr 30;113(18):4153-62
pubmed: 19141862
Blood. 2017 Oct 19;130(16):1832-1844
pubmed: 28790105
Blood. 2008 Feb 15;111(4):1827-33
pubmed: 18048644
Comput Methods Programs Biomed. 2007 Nov;88(2):95-101
pubmed: 17850917

Auteurs

Aleksandr Lazaryan (A)

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA aleksandr.lazaryan@moffitt.org.

Michelle Dolan (M)

University of Minnesota Medical Center, Minneapolis, MN, USA.

Mei-Jie Zhang (MJ)

CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA.

Hai-Lin Wang (HL)

CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Mohamed A Kharfan-Dabaja (MA)

Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA.

David I Marks (DI)

Adult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, UK.

Nelli Bejanyan (N)

Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA.

Edward Copelan (E)

Levine Cancer Institute, Atrium Health, Carolinas HealthCare System, Charlotte, NC, USA.

Navneet S Majhail (NS)

Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.

Edmund K Waller (EK)

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Nelson Chao (N)

Division of Cell Therapy and Hematology, Department of Medicine, Duke University Medical Center, Durham, NC, USA.

Tim Prestidge (T)

Blood and Cancer Centre, Starship Children's Hospital, Auckland, New Zealand.

Taiga Nishihori (T)

Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Partow Kebriaei (P)

Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, TX, USA.

Yoshihiro Inamoto (Y)

Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

Betty Hamilton (B)

Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.

Shahrukh K Hashmi (SK)

Department of Internal Medicine, Mayo Clinic, MN, USA.
Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Rammurti T Kamble (RT)

Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.

Ulrike Bacher (U)

Department of Hematology, Inselspital, Bern University Hospital, Switzerland.

Gerhard C Hildebrandt (GC)

Markey Cancer Center, University of Kentucky, Lexington, KY, USA.

Patrick J Stiff (PJ)

Loyola University Medical Center, Maywood, IL, USA.

Joseph McGuirk (J)

University of Kansas Medical Center, Westwood, KS, USA.

Ibrahim Aldoss (I)

City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Amer M Beitinjaneh (AM)

University of Miami, Miami, FL, USA.

Lori Muffly (L)

Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA, USA.

Ravi Vij (R)

Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO, USA.

Richard F Olsson (RF)

Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.

Michael Byrne (M)

Vanderbilt University Medical Center, Nashville, TN, USA.

Kirk R Schultz (KR)

Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia's Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada.

Mahmoud Aljurf (M)

Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Matthew Seftel (M)

Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, Manitoba, Canada.

Mary Lynn Savoie (ML)

Tom Baker Cancer Centre, Calgary, Alberta, Canada.

Bipin N Savani (BN)

Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Leo F Verdonck (LF)

Department of Hematology/Oncology, Isala Clinic, Zwolle, the Netherlands.

Mitchell S Cairo (MS)

Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, New York Medical College, Valhalla, NY, USA.

Nasheed Hossain (N)

Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA.

Vijaya Raj Bhatt (VR)

The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.

Haydar A Frangoul (HA)

The Children's Hospital at TriStar Centennial and Sarah Cannon Research Institute, Nashville, TN, USA.

Hisham Abdel-Azim (H)

Division of Hematology, Oncology and Blood & Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.

Monzr Al Malki (MA)

City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Reinhold Munker (R)

Section of Hematology/Oncology, Department of Internal Medicine, Louisiana State University Health Shreveport, Shreveport, LA, USA.

David Rizzieri (D)

Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.

Nandita Khera (N)

Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA.

Ryotaro Nakamura (R)

Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.

Olle Ringdén (O)

Translational Cell Therapy Group, CLINTEC (Clinical Science, Intervention and Technology), Karolinska Institutet, Stockholm Sweden.

Marjolein van der Poel (M)

Academische Ziekenhuis Maastricht, Maastricht, the Netherlands.

Hemant S Murthy (HS)

Mayo Clinic Florida, Jacksonville, FL, USA.

Hongtao Liu (H)

University of Chicago Medicine, Chicago, IL, USA.

Shahram Mori (S)

Blood & Marrow Transplant Center, Florida Hospital Medical Group, Orlando, FL, USA.

Satiro De Oliveira (S)

UCLA Medical Center, Los Angeles, CA, USA.

Javier Bolaños-Meade (J)

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.

Mahmoud Elsawy (M)

QE II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada.

Pere Barba (P)

Hospital Vall d'Hebron, Barcelona, Spain.

Sunita Nathan (S)

Rush University Medical Center, Chicago, IL, USA.

Biju George (B)

Christian Medical College, Vellore, India.

Attaphol Pawarode (A)

Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI, USA.

Michael Grunwald (M)

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

Vaibhav Agrawal (V)

Division of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, IN, USA.

Youjin Wang (Y)

National Cancer Institute (NCI), Rockville, MD, USA.

Amer Assal (A)

New York Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA.

Paul Castillo Caro (PC)

UF Health Shands Children's Hospital, Gainesville, FL, USA.

Yachiyo Kuwatsuka (Y)

Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.

Sachiko Seo (S)

Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.

Celalettin Ustun (C)

Division of Hematology/Oncology/Cell Therapy, Rush University, Chicago, IL, USA.

Ioannis Politikos (I)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Hillard M Lazarus (HM)

Case Western Reserve University, Cleveland, OH, USA.

Wael Saber (W)

CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Brenda M Sandmaier (BM)

Division of Medical Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Marcos De Lima (M)

Department of Medicine, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA.

Mark Litzow (M)

Division of Hematology and Transplant Center, Mayo Clinic Rochester, Rochester, MN, USA.

Veronika Bachanova (V)

Blood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN, USA.

Daniel Weisdorf (D)

Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Impact of cytogenetic abnormalities on...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Aberrations des chromosomes › Impact of cytogenetic abnormalities on...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › Impact of cytogenetic abnormalities on...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Impact of cytogenetic abnormalities on...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › Impact of cytogenetic abnormalities on...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Leucémie lymphoïde › Leucémie-lymphome lymphoblastique à précurseurs B et T › Impact of cytogenetic abnormalities on...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Impact of cytogenetic abnormalities on...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunosuppression thérapeutique › Conditionnement pour greffe › Impact of cytogenetic abnormalities on...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation homologue › Impact of cytogenetic abnormalities on...